Constitutional loss-of-function pathogenic variants in the tumor suppressor genes BRCA1 and BRCA2 are widely known to confer an elevated risk of breast and/or ovarian cancer, and their mutational screening has become a standard in routine diagnostic practice. This evidence concerns the gene BRCA1 and ovarian carcinoma.